Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vector Development
Long-Term Gene Delivery Using Lentiviral Vectors Reported
November 24th, 1997
Cell Genesys, Inc., Foster City, California, announced that company collaborators at The Salk Institute have achieved successful long-term gene delivery to liver and muscle tissues using second generation lentiviral vectors. The data demonstrate that following a single injection, gene expression was detected for at least six months and potentially indefinitely. These preclinical studies were described in the November 1997 issue of the journal Nature Genetics. Cell Genesys is the exclusive worldwide licensee of the lentiviral gene delivery technology which was developed at The Salk Institute by Inder Verma, Ph.D. and colleagues. Company scientists,...
Source: Cancer Weekly (1997-11-24)
|
